Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Palopegteriparatide by Ascendis Pharma for Hypoparathyroidism: Likelihood of Approval
Palopegteriparatide is under clinical development by Ascendis Pharma and currently in Pre-Registration for Hypoparathyroidism. According to GlobalData, Pre-Registration drugs for...
ACP-017 by Ascendis Pharma for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
ACP-017 is under clinical development by Ascendis Pharma and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According...
ACP-017 by Ascendis Pharma for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
ACP-017 is under clinical development by Ascendis Pharma and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
ACP-017 by Ascendis Pharma for Merkel Cell Carcinoma: Likelihood of Approval
ACP-017 is under clinical development by Ascendis Pharma and currently in Phase II for Merkel Cell Carcinoma. According to GlobalData,...
ACP-017 by Ascendis Pharma for Esophageal Cancer: Likelihood of Approval
ACP-017 is under clinical development by Ascendis Pharma and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...
ACP-017 by Ascendis Pharma for Vulvar Cancer: Likelihood of Approval
ACP-017 is under clinical development by Ascendis Pharma and currently in Phase II for Vulvar Cancer. According to GlobalData, Phase...
ACP-017 by Ascendis Pharma for Vaginal Cancer: Likelihood of Approval
ACP-017 is under clinical development by Ascendis Pharma and currently in Phase II for Vaginal Cancer. According to GlobalData, Phase...
ACP-017 by Ascendis Pharma for Non-Small Cell Lung Cancer: Likelihood of Approval
ACP-017 is under clinical development by Ascendis Pharma and currently in Phase II for Non-Small Cell Lung Cancer. According to...
ACP-017 by Ascendis Pharma for Anal Cancer: Likelihood of Approval
ACP-017 is under clinical development by Ascendis Pharma and currently in Phase II for Anal Cancer. According to GlobalData, Phase...
ACP-017 by Ascendis Pharma for Hepatocellular Carcinoma: Likelihood of Approval
ACP-017 is under clinical development by Ascendis Pharma and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...
ACP-017 by Ascendis Pharma for Gastric Cancer: Likelihood of Approval
ACP-017 is under clinical development by Ascendis Pharma and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...
ACP-017 by Ascendis Pharma for Cervical Cancer: Likelihood of Approval
ACP-017 is under clinical development by Ascendis Pharma and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...
ACP-017 by Ascendis Pharma for Oral Cavity (Mouth) Cancer: Likelihood of Approval
ACP-017 is under clinical development by Ascendis Pharma and currently in Phase II for Oral Cavity (Mouth) Cancer. According to...
ACP-017 by Ascendis Pharma for Oropharyngeal Cancer: Likelihood of Approval
ACP-017 is under clinical development by Ascendis Pharma and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase...
ACP-017 by Ascendis Pharma for Laryngeal Cancer: Likelihood of Approval
ACP-017 is under clinical development by Ascendis Pharma and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase...
ACP-017 by Ascendis Pharma for Hypopharyngeal Cancer: Likelihood of Approval
ACP-017 is under clinical development by Ascendis Pharma and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase...
ACP-017 by Ascendis Pharma for Human Papillomavirus (HPV) Associated Cancer: Likelihood of Approval
ACP-017 is under clinical development by Ascendis Pharma and currently in Phase II for Human Papillomavirus (HPV) Associated Cancer. According...
Navepegritide by Ascendis Pharma for Achondroplasia: Likelihood of Approval
Navepegritide is under clinical development by Ascendis Pharma and currently in Phase III for Achondroplasia. According to GlobalData, Phase III...
Risk adjusted net present value: What is the current valuation of Ascendis Pharma's TransCon CNP?
TransCon CNP is a synthetic peptide commercialized by Ascendis Pharma, with a leading Phase III program in Achondroplasia. According to...
Risk adjusted net present value: What is the current valuation of Ascendis Pharma's TransCon IL-2 beta/gamma?
TransCon IL-2 beta/gamma is a recombinant protein commercialized by Ascendis Pharma, with a leading Phase II program in Cervical Cancer....